Free tool
FAERS Monitor: Revatio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203109 or its brand name (Revatio, Sildenafil Citrate). Reports on generic versions are filed under their own applications.
Reports
55,254
Serious
38,247
69% of reports
Hospitalization
23,887
Death reported
10,436
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea8,445
- headache5,765
- death5,676
- diarrhoea4,437
- nausea3,833
- fatigue3,640
- dizziness3,413
- cough3,389
- pneumonia3,057
- malaise2,716
- fluid retention2,314
- hypotension2,215
- vomiting2,113
- off label use2,014
- drug ineffective1,937
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 60 |
| 2005 | 120 |
| 2006 | 309 |
| 2007 | 259 |
| 2008 | 493 |
| 2009 | 696 |
| 2010 | 1,588 |
| 2011 | 2,325 |
| 2012 | 2,533 |
| 2013 | 2,825 |
| 2014 | 5,734 |
| 2015 | 4,431 |
| 2016 | 3,367 |
| 2017 | 4,035 |
| 2018 | 3,584 |
| 2019 | 3,653 |
| 2020 | 3,427 |
| 2021 | 2,839 |
| 2022 | 2,721 |
| 2023 | 2,774 |
| 2024 | 2,725 |
| 2025 | 2,704 |
| 2026 | 2,052 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,998,905 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fluid retentionSignal | 2,314 | 18.1 | 17.4 | 35,746 |
| dyspnoeaSignal | 8,445 | 5.7 | 5.6 | 33,537 |
| coughSignal | 3,389 | 4.6 | 4.5 | 9,700 |
| hypotensionSignal | 2,215 | 4.2 | 4.1 | 5,471 |
| pneumoniaSignal | 3,057 | 3.6 | 3.5 | 5,826 |
| headacheSignal | 5,765 | 3.5 | 3.4 | 10,638 |
| diarrhoeaSignal | 4,437 | 2.6 | 2.6 | 4,582 |
| dizzinessSignal | 3,413 | 2.6 | 2.5 | 3,464 |
| deathSignal | 5,676 | 2.5 | 2.5 | 5,378 |
| malaiseSignal | 2,716 | 2.4 | 2.3 | 2,172 |
| nausea | 3,833 | 1.8 | 1.8 | 1,540 |
| fatigue | 3,640 | 1.8 | 1.7 | 1,294 |
| vomiting | 2,113 | 1.7 | 1.6 | 639 |
| off label use | 2,014 | 0.9 | 0.8 | 37 |
| drug ineffective | 1,937 | 0.6 | 0.5 | 718 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.